Genesis Bioventures (GBIW) Announces Breast Cancer Marker Granted European Diagnostic and Therapeutic Patent Approval
6/19/2007 2:03:50 PM
LOS ANGELES--(BUSINESS WIRE)--Genesis Bioventures, Inc. (OTCBB:GBIW) announced today that Mammastatin, the breast cancer marker exclusively licensed to the Company by the University of Michigan, was granted an additional Patent from the European Patent Office for diagnostic and therapeutic uses. The Mammastatin technology is developed for use as the Mammastatin Serum Assay, a breast cancer risk assessment test developed by Biomedical Diagnostics, the Company’s subsidiary.
comments powered by